---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: STRIDE"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: STRIDE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 66 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/stride"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: STRIDE

<a id="heading-3.1.4"></a>

## 3.1.4 STRIDE

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Objective in the published article

> “To assess clinical efficacy, safety, and pharmacokinetics of ESK-001 compared to placebo in patients with moderate-to-severe plaque psoriasis.”
> “The phase 2 STRIDE study aimed to assess the efficacy, safety, tolerability, and PK characteristics across a range of ESK-001 doses versus placebo during 12 weeks of treatment in adults with moderate-to-severe plaque psoriasis.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.1-2"></a>

#### Main and secondary objectives in the EU Clinical Trials Register

> “E.2.1 Main objective of the trial To compare the Psoriasis Area and Severity Index (PASI-75) between doses of ESK-001 and placebo after 12 weeks of treatment”
> “1.To assess the safety and tolerability of ESK-001 dose in moderate to severe psoriasis patients.”
> “2. To characterize the pharmacokinetics (PK) of ESK-001.”
> “3.To assess the response rate in static Physician’s Global Assessment (sPGA) score after 12 weeks of treatment.”
> “4.To assess the response rate in PASI-50,90, and 100 score after 12 weeks of treatment.”
> “5.To compare the response rate in PASI-75 among ESK-001 treatments.”
> “6.To assess the effect on body surface area (%BSA) involved with psoriasis after 12 weeks of treatment.”
> “7.To assess the change in Dermatology Life Quality Index (DLQI)”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="topic-3.1.4.1-3"></a>

#### Purpose of the study in the protocol synopsis

> “The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of ESK-001 compared to placebo in patients with moderate to severe psoriasis.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-09-27”
> “Primary Completion (Actual) 2023-06-29”
> “Study Completion (Actual) 2023-07-25”
> “First Posted 2022-10-31”
> “Results First Posted 2024-07-23”

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

<a id="topic-3.1.4.2-2"></a>

#### Number of sites in the published article, the ClinicalTrials.gov record, and the protocol

> “A total of 228 patients were enrolled from 30 sites in North America and Europe beginning in September 2022.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

> “This study has 53 locations”

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

> “Study will be conducted at approximately 65 sites in North America and Europe.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.2-3"></a>

#### Countries of trial sites in the ClinicalTrials.gov record

| Country | First site listed for the country in the record |
| --- | --- |
| United States | “Birmingham, Alabama, United States, 35205” |
| Canada | “Edmonton, Alberta, Canada, T6G 1C3” |
| Czechia | “Nový Jičín, Czechia, 741 01” |

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

<a id="topic-3.1.4.2-4"></a>

#### Planned regions, planned sites, authorization dates, and end date in the EU Clinical Trials Register

> “E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned Canada United States Czechia Poland”
> “E.8.4.1 Number of sites anticipated in Member State concerned 5”
> “E.8.5.1 Number of sites anticipated in the EEA 15”
> “Date of Competent Authority Decision 2023-01-30”
> “Date of Ethics Committee Opinion 2023-02-07”
> “Date of the global end of the trial 2023-07-25”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Randomized, double-blinded, placebo-controlled 16-week design with stratified randomization in the published article

> “STRIDE (NCT05600036, EudraCT Number 2022-002633-34) was a phase 2, double-blinded, 16-week study with patients randomized to 6 treatment groups for 12 weeks of placebo or ESK-001, ranging from 10 mg QD to 40 mg BID.”
> “ESK-001-006 (STRIDE) was a randomized, double-blinded, placebo-controlled, 16-week study consisting of a screening period (up to 4 weeks), treatment period (12 weeks), and safety follow-up period (4 weeks)”
> “Randomization was stratified by prior use of biologics and geographic region.”
> “The study patients, investigators, study personnel at sites, and sponsor representatives on the clinical study team were all blinded to treatment assignments.”
> “After completing the study, patients were eligible to receive ESK-001 treatment in an open-label extension study (ESK-001-007, NCT05739435).”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.3-2"></a>

#### Design in the ClinicalTrials.gov record

> “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis”
> “This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.”
> “This study will consist of a 4 week screening period, 12 week treatment period, and a 4 week follow up period for a total of 20 weeks.”

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

| Design field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Triple (ParticipantInvestigatorOutcomes Assessor)” |

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

<a id="topic-3.1.4.3-3"></a>

#### Design fields in the EU Clinical Trials Register

> “E.7.2 Therapeutic exploratory (Phase II) Yes”
> “E.8.1.4 Double blind Yes”
> “E.8.1.5 Parallel group No”
> “E.8.2.4 Number of treatment arms in the trial 6”
> “E.8.7 Trial has a data monitoring committee Yes”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="topic-3.1.4.3-4"></a>

#### Study duration and safety monitoring committee in the protocol

> “The total duration of study participation for each patient will be approximately 20 weeks.”
> “A safety monitoring committee (SMC) comprising representatives from the Sponsor, clinical research organization (CRO), two independent physicians and a statistician will be utilized in this study.”
> “The SMC will initially convene to review all available safety data after approximately 50 patients have been randomized and completed their Week 4 visit.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Inclusion criteria in the protocol

> “1. Able and willing to provide signed informed consent to participate in this study”
> “2. Males or females, age 18-75 years, inclusive, at the Screening Visit”
> “3. Total body weight >40 kg (88 lb)”
> “4. Diagnosis of plaque psoriasis for ≥6 months”
> “5. Plaques covering ≥10% of body surface area (BSA)”
> “6. Psoriasis area severity index (PASI) score ≥12 and static Physician’s Global Assessment (sPGA) score ≥3”
> “7. Women of childbearing potential (WOCBP) must agree to adhere to highly effective methods of contraception for the entirety of the study and for 30 days after the last dose of study drug”
> “8. Males who are sexually active with WOCBP must agree to use highly effective methods of contraception for the entirety of the study and for 90 days after the last dose of study drug”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.4-2"></a>

#### Exclusion criteria on psoriasis type, associated conditions, psoriatic arthritis, and pregnancy in the protocol

> “1. Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic, drug induced)”
> “2. Diagnosis of immune-mediated conditions that are commonly associated with psoriasis (e.g., uveitis, inflammatory bowel disease) or other inflammatory skin conditions that may interfere with the study assessment”
> “3. Patients with psoriatic arthritis who are receiving systemic (oral, SC, IM or IV) immunosuppressant medications (including corticosteroids, immunosuppressant biologics) or who has or is expected, in the opinion of the investigator, to develop unstable disease.”
> “4. Pregnant, lactating, or planning to get pregnant during the study period”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.4-3"></a>

#### Exclusion criteria on prior treatment washout and lack of response to biologic therapies in the protocol

> “5. Has used topical medications/treatments that could affect psoriasis evaluation within 2 weeks of the first administration of study drug”
> “6. Has received phototherapy or any systemic medications/treatments that could affect psoriasis evaluation within 4 weeks of Study Day 1”
> “7. Has received any therapeutic agent targeted to: IL-12or IL-23 within 6 months, IL-17 within 4 months, or any TNFα inhibitor(s) within 2 months of first administration of study drug”
> “8. Is currently receiving or has received any systemic immunosuppressants or immunomodulatory drugs (e.g., methotrexate, cyclosporine) within 4 weeks of the first administration of study drug or 5 half-lives whichever is longer”
> “9. Has received agents that modulate B cells (e.g., rituximab, ocrelizumab) within 6 months of first administration of study drug”
> “10. Has received agents that modulate T cells (e.g., abatacept, alemtuzumab) within 3 months of first administration of study drug”
> “11. Has received JAK inhibitors (e.g., baricitinib, tofacitinib) or TYK2 inhibitors within 4 weeks of first administration of study drug”
> “12. History of lack of clinical response to any therapeutic agent targeted to IL-12, IL-17 or IL-23 (e.g., ustekinumab, risankizumab, secukinumab, ixekizumab) at approved doses after at least 3 months of treatment”
> “13. History of lack of clinical response, in the Investigator’s opinion, to 2 or more biologic therapies at approved doses after at least 3 months of treatment”
> “14. Has received any investigational agent, within 30 days or 5 half-lives (whichever is longer) of any study drug or is currently enrolled in an investigational study”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.4-4"></a>

#### Exclusion criteria on QTcF, cardiovascular disease, infections, and laboratory values in the protocol

> “16. Patients with QTcF >450 msec (males) or >470 msec (females) at screening”
> “17. Unstable cardiovascular disease, defined as a recent clinical deterioration (e.g., unstable angina, rapid atrial fibrillation) or a cardiac hospitalization within the last 3 months”
> “18. Active herpes viral infection, including herpes simplex 1 and 2 and herpes zoster identified on examination and/or medical history within 2 months of administration of study drug”
> “19. Patients with hepatitis C virus (HCV), or hepatitis B virus (HBV) or human immunodeficiency virus (HIV) or active or inadequately treated latent tuberculosis (TB) infection at screening”
> “20. Has any of the following lab abnormalities:”
> “Absolute neutrophil count <1.5 X 10^9/L”
> “Hemoglobin <9 g/dL”
> “AST/ALT ≥2 x upper limit of normal (ULN)”
> “Albumin <3 g/dL”
> “Total bilirubin ≥2 x ULN (patients with a history of Gilbert’s syndrome are not eligible)”
> “Glomerular filtration rate <50 (Cockcroft and Gault method)”
> “22. History of serious bacterial, fungal, or viral infections that led to hospitalization and IV antibiotic treatment within 90 days prior to screening, or any recent serious infection requiring antibiotic treatment within 30 days of Study Day 1”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.4-5"></a>

#### Exclusion criteria on corticosteroid-requiring conditions, malignancy, live vaccines, surgery, and mental illness in the protocol

> “21. History of any immune-mediated or inflammatory medical condition for which patient requires current systemic (oral, SC, IM or IV) corticosteroids”
> “23. Known current malignancy or current evaluation for a potential malignancy or history of malignancy within the past 5 years prior to screening, except for adequately treated basal cell skin carcinoma, carcinoma in situ of the cervix and breast ductal carcinoma in situ”
> “24. Live vaccines (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and bacillus Calmette-Guérin) within 4 weeks of Study Day 1”
> “25. Patient has a known hypersensitivity to any component of the study drug”
> “26. Patient has planned surgery during the study period”
> “27. Any acute or chronic illness/condition or evidence of an unstable clinical condition that in the investigator’s judgement will substantially increase the risk to the patient if he or she participates in the study”
> “28. History of mental illness within the last 5 years, unless the patient fulfills one of the following conditions:”
> “Receiving a fixed regimen of psychiatric medications for at least 6 months before screening, displays no sign of acute mental illness and, in the opinion of the investigator, the patient is able and safe to participate in the study”
> “Has not required or been prescribed any psychiatric medication (including but not limited to antidepressants or anxiolytics) within 12 months before screening and, in the opinion of the investigator, the patient is able and safe to participate in the study”
> “29. Patient who, for any reason, is deemed by the investigator to be inappropriate for this study or is unable to comply with the study protocol”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.4-6"></a>

#### Body mass index added to the weight criterion in the EU Clinical Trials Register

> “Total body weight >40 kg (88 lb), BMI > 18 kg/m2”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="topic-3.1.4.4-7"></a>

#### Eligibility criteria summarized in the supplementary material of the published article

> “Eligible patients were adults with plaque psoriasis between the ages of 18-75 years with a total body weight >40 kg (88 lb), a diagnosis of plaque psoriasis for ≥6 months, body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) ≥12 and static Physician’s Global Assessment (sPGA) score ≥3 at baseline.”
> “Key patient exclusion criteria included presence of unstable medical conditions, active viral infections, active or untreated latent tuberculosis, or current malignancy.”
> “Patients who had been previously unresponsive to agents targeting IL-12, IL-23, or IL-17, patients who had failed more than 2 biologics, or patients who had received any investigational treatment within 30 days or 5 half-lives of treatment with study drug were excluded from the study.”

Source: [Blauvelt et al. (2025b)](https://data.mendeley.com/public-files/datasets/zs5xvkwpym/files/d4eed96a-ef9b-421e-91a5-551459647784/file_downloaded)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Dose groups, randomization, administration, and placebo matching in the published article

> “On day 1, eligible patients were randomized equally into 1 of 6 treatment groups (ESK-001 10 mg once daily [QD], 20 mg QD, 40 mg QD, 20 mg twice daily [BID], 40 mg BID, or placebo).”
> “Patients were directed to take study drug tablets orally with or without food.”
> “Placebo tablets were matched for shape, size, and color.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.5-2"></a>

#### Arms and tablet regimens in the ClinicalTrials.gov results

| Arm | Arm description in the results |
| --- | --- |
| ESK-001 10 mg QD | “ESK-001 10mg tablet once a day” |
| ESK-001 20 mg QD | “ESK-001 20mg tablet once a day” |
| ESK-001 40 mg QD | “ESK-001 40mg tablet once a day” |
| ESK-001 20 mg BID | “ESK-001 20mg tablet twice a day” |
| ESK-001 40 mg BID | “ESK-001 40mg tablet twice a day” |
| Placebo | “Placebo tablet” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="topic-3.1.4.5-3"></a>

#### Randomization ratio across five dose levels and placebo in the protocol

> “Patients fulfilling all eligibility criteria will be randomized in a 1:1:1:1:1:1 manner to receive oral doses of ESK-001 at one of 5 dose levels”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using PASI 75 Response as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Primary, secondary, and exploratory efficacy end points in the published article

> “The primary efficacy end point was the proportion of patients achieving ≥75% reduction from baseline Psoriasis Area and Severity Index (PASI) at 12 weeks between ESK-001 dose groups and placebo.”
> “The secondary efficacy end points measured at week 12 included proportions of patients achieving PASI-50, 90, or 100; proportion of patients achieving a static Physician's Global Assessment (sPGA) score of “0” (“clear skin”) or “1” (“minimal disease”); and changes from baseline in % body surface area compared to placebo.”
> “End points assessing patient-reported outcomes at week 12 compared to placebo included the secondary end point of change from baseline in Dermatology Life Quality Index (DLQI) and the exploratory end point of change from baseline in pruritus numerical rating scale score for worst or on-average severity of itch over the prior 24 hours.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.6.1-2"></a>

##### Safety and pharmacokinetic outcomes in the published article

> “Safety outcomes included the incidence of treatment-emergent adverse events (TEAEs), serious adverse events, laboratory test results, and electrocardiogram parameters.”
> “AEs were coded according to the Medical Dictionary for Regulatory Activities, version 25.0.”
> “Key parameters, including Cmax (maximum (or peak) serum concentration), Ctrough (concentration reached by a drug immediately before the next dose is administered), and Tmax (time of peak plasma concentration), were assessed using population PK modeling and noncompartmental analysis, providing a characterization of ESK-001's PK profile and variability within the study population.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.6.1-3"></a>

##### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Outcome type | Outcome measure | Measure description | Time frame |
| --- | --- | --- | --- |
| Primary | “To Compare the Psoriasis Area and Severity Index (PASI-75) Between Doses of ESK-001 and Placebo” | “Proportion of patients with moderate to severe psoriasis achieving ≥75% reduction in PASI score” | “12 weeks” |
| Secondary | “To Assess the Safety and Tolerability of ESK-001 Dose in Moderate to Severe Psoriasis Patients” | “Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). See Adverse Events section.” | “12 weeks” |
| Secondary | “To Assess the Response Rate in Static Physician's Global Assessment (sPGA) Score” | “Proportion of patients achieving an sPGA score of "0" ("cleared") or "1" ("minimal")” | “12 weeks” |
| Secondary | “To Characterize the Pharmacokinetics (PK) of ESK-001” | “Plasma concentrations and PK parameters of ESK-001.” | “14 weeks” |

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

<a id="topic-3.1.4.6.1-4"></a>

##### Pharmacokinetic outcome measures at registration, October 2022, superseded in June 2024

> “Plasma concentrations and PK parameters including steady-state maximum observed concentration (Cmax) for ESK-001 at Week 8”
> “Plasma concentrations and PK parameters including steady-state trough observed plasma concentration (Ctrough) for ESK-001 at Week 8”

Source: [ClinicalTrials.gov NCT05600036 version 1](https://clinicaltrials.gov/study/NCT05600036?tab=history&a=1)

<a id="topic-3.1.4.6.1-5"></a>

##### Primary and secondary end points in the EU Clinical Trials Register

> “Proportion of patients with moderate to severe psoriasis achieving ≥75% reduction in PASI score at 12 weeks between doses of ESK-001 and placebo”
> “Proportion of patients achieving PASI-75 at 12 weeks compared among the ESK-001 treatments”
> “Change from baseline in %BSA after 12 weeks of ESK-001 treatment compared with placebo.”
> “Change from baseline in DLQI at Week 12 in ESK-001 compared with placebo”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="topic-3.1.4.6.1-6"></a>

##### Exploratory end points in the protocol

> “Change from baseline in NRS score after 12 weeks of ESK-001 treatment compared with placebo”
> “Change from baseline in EQ-5D at Week 12 in ESK-001 compared with placebo”
> “Change from baseline in transcriptomic and proteomic expression in response to ESK-001 treatment”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.6.1-7"></a>

##### PASI and sPGA scoring and the timepoint of the PASI-based end points in the protocol

> “The PASI system derives a score for the severity of psoriatic lesions by evaluating erythema, induration, and scaling in each of 4 body regions, as detailed in Appendix A. The primary and secondary endpoints are based on the PASI response at the end of treatment (12-week timepoint).”
> “The PASI is a grading system used for the evaluation of the severity of psoriatic lesions and their response to treatment. The PASI produces a numeric score that can range from 0 to 72.”
> “The Physician Global Assessment (PGA) is used to determine the subject’s psoriasis lesions overall at a given time point.”
> “0 = Cleared, except for residual discoloration”
> “1 = Minimal - majority of lesions have individual scores for I + E + S / 3 that averages 1”
> “5 = Severe - majority of lesions have individual scores for I + E + S / 3 that averages 5”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.6.1-8"></a>

##### Responder definitions for DLQI and pruritus NRS in the statistical analysis plan

> “The primary endpoint is the proportion of subjects achieving >=75% reduction in PASI score (PASI-75) at Week 12.”
> “The two questions collected in NRS questionnaire will be assessed separated as the average itch within the past 24 hours and the worst itch within the past 24 hours.”
> “Additionally, a responder analysis will be conducted for DLQI where a responder is defined as the subject who achieved a post-baseline score of 0 or 1.”
> “A responder analysis will also be conducted for NRS questionnaire where a responder is defined as a subject who has achieved a post-baseline itch score of < 4.”

Source: [Alumis STRIDE statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/SAP_001.pdf)

<a id="topic-3.1.4.6.1-9"></a>

##### Regulatory guidance on dose-finding designs and on the duration needed to show short-term efficacy

> “The dose-finding studies should be randomised, and placebo-controlled using parallel group design.”
> “The studies should characterise the most beneficial part of the dose-response curve and use at least 3 dosages to establish the optimal dose compared to placebo.”
> “A duration of 8 to 12 weeks (4 weeks for a potent topically applied corticosteroid) is generally sufficient to show short-term efficacy, except for drugs with slow onset of action, where longer study duration may be needed.”

Source: [EMA psoriasis clinical investigation guideline (2004)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Sample size calculation in the published article

> “The sample size was determined based on the primary efficacy end point. Calculations were based on a 1:1:1:1:1:1 randomization ratio and provided at least 99% power to detect an absolute difference in the PASI-75 response rate of at least 50% in an active group compared to placebo.”
> “A sample size of 35 patients per dose group was estimated with a two-sided, two-sample t-test at a significance level of 0.05.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.7.1-2"></a>

##### Planned enrollment and sample size assumptions in the protocol

> “Approximately 210 patients will be randomly assigned to one of the 6 study arms (35 patients per arm).”
> “The Sponsor may choose, based on the evolving data (e.g., safety) from ESK-001 studies, to enroll up to 50 additional patients.”
> “Calculations are based on a 1:1:1:1:1:1 randomization ratio (ESK-001 doses 1-5 vs. placebo) and will provide at least 99% power to detect 50% increase in the PASI-75 response rate in an active arm (i.e., 60% response rate) compared to the placebo assuming the response rate is 10% in the placebo arm.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.7.1-3"></a>

##### Planned enrollment in the EU Clinical Trials Register

> “F.4.1 In the member state 30”
> “F.4.2.1 In the EEA 60”
> “F.4.2.2 In the whole clinical trial 210”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="topic-3.1.4.7.1-4"></a>

##### Estimated enrollment at registration in the ClinicalTrials.gov record

> “Enrollment 210 [Estimated]”

Source: [ClinicalTrials.gov NCT05600036 version 1](https://clinicaltrials.gov/study/NCT05600036?tab=history&a=1)

<a id="topic-3.1.4.7.1-5"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 228”

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

<a id="topic-3.1.4.7.1-6"></a>

##### Participants per arm in the intent-to-treat, modified intent-to-treat, and safety analysis sets of the published article

| Analysis set (table) | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
| --- | --- | --- | --- | --- | --- | --- |
| Intent-to-treat (Table I) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 40)” | “(N = 39)” | “(N = 39)” |
| Modified intent-to-treat (Table II) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 39)” | “(N = 39)” | “(N = 39)” |
| Safety (Table III) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 39)” | “(N = 39)” | “(N = 39)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

| Analysis set (table) | Pooled ESK-001 column header |
| --- | --- |
| Intent-to-treat (Table I) | “ESK-001 pooled (N = 190)” |
| Safety (Table III) | “ESK-001 pooled (N = 189)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Efficacy and safety analysis populations, statistical tests, and missing-data handling in the published article

> “All efficacy analyses were based on the modified intent-to-treat population, which included randomized patients who received at least 1 dose of study drug with analyses conducted according to the randomized treatment.”
> “All efficacy responder-type end points were assessed with the Cochran-Mantel-Haenszel test and adjusted for stratification factors.”
> “A nonresponder imputation was applied to responder analyses in which patients who dropped out of the study before week 12 were considered as nonresponders at the week 12 visit.”
> “Safety analyses included all patients who received at least 1 dose of either ESK-001 or placebo.”
> “Subjects were analyzed according to the actual treatment received for safety analyses.”
> “Baseline in this study was defined as the last available data on or prior to the time of the first dose of study drug.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.7.2-2"></a>

##### Analysis sets named in the table captions and notes of the published article

> “Demographic and baseline characteristics of STRIDE study (ITT analysis set)”
> “Summary of efficacy outcomes at Week 12 of STRIDE study (mITT analysis set)”
> “The modified intent-to-treat (mITT) analysis set includes all randomized patients who received ≥1 dose analyzed based on their randomized treatment. For patients with missing data at week 12, a nonresponder imputation (NRI) was applied for all responder end points.”
> “P values were calculated by comparing the proportion in each active arm vs placebo using the Cochrane-Mantel-Haenszel test adjusted for randomization stratification factors.”
> “Summary of TEAEs in STRIDE study (safety analysis set)”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.7.2-3"></a>

##### Analysis populations, stratification factors, multiplicity, and treatment-emergent period in the statistical analysis plan

> “Modified Intent-to-Treat (mITT) Population: All randomized subjects who received at least one dose of study drug, with analyses conducted according to the assigned treatment. This will be the analysis population used for the primary efficacy analysis at Week 12.”
> “Intent-to-treat (ITT) Population: All randomized subjects, regardless of whether they receive study drug, with analyses conducted according to the assigned treatment.”
> “Per-protocol (PP) Population: All subjects in the ITT population who have received at least one dose of study drug as assigned, have both baseline and at least one post-baseline PASI score, and have no important protocol deviations (IPD) which may affect key primary and secondary efficacy endpoints in the treatment period.”
> “Safety Analysis Population: All randomized subjects who receive at least one dose of study drug with analyses conducted by actual treatment received.”
> “PK Analysis Population: All randomized subjects who receive at least 1 dose of ESK-001 and have at least one non-missing PK concentration with analysis conducted by actual treatment received.”
> “Prior use of biologics or JAK inhibitors (yes/no)”
> “Geographic region (North America /rest of world (ROW))”
> “No adjustments for multiplicity control will be performed in this study.”
> “The treatment emergent period is defined as first dose through the end of study for subjects who complete the full treatment period of 12 weeks.”
> “If a subject discontinues study drug early, then the treatment emergent period will be first dose through four weeks after last dose.”
> “Since the EQ-5D-5L value sets used to calculate the index score are country-specific and there currently are none available for Czech Republic where some subjects are enrolled in this study, the value set for Poland will be used instead as the closest Eastern European country with available scoring instrument.”

Source: [Alumis STRIDE statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/SAP_001.pdf)

<a id="topic-3.1.4.7.2-4"></a>

##### Intent-to-treat efficacy analysis planned in the protocol

> “Efficacy analyses will be based on the intent-to-treat (ITT) approach. All patients randomized (ITT population) will be included in the analysis, and subjects will be analyzed according to their randomized treatment.”
> “Unless otherwise noted, analyses of efficacy outcome measures will be stratified by prior use of biologics and geographic region.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.7.2-5"></a>

##### Analysis population for each outcome measure in the ClinicalTrials.gov results

| Outcome measure | Analysis population description |
| --- | --- |
| PASI-75 (primary) | “Analysis Population Description All Randomized and Treated Participants” |
| Safety and tolerability | “Analysis Population Description Safety Analysis Set” |
| sPGA response | “Analysis Population Description mITT population” |
| Pharmacokinetics | “Analysis Population Description PK Analysis Set” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Randomized, dosed, completed, and discontinued participants in the published article

> “Of the 228 patients randomized to placebo or 1 of 5 ESK-001 doses, a total of 227 patients were dosed in this phase 2 study”
> “A total of 204 patients (89.5%) completed the study.”
> “Overall, study discontinuation was similar between treatment groups, with 18 (9%) patients in ESK-001 groups and 5 (13%) patients in the placebo group discontinuing”
> “Five patients (2.6%) discontinued ESK-001 due to an AE.”
> “Withdrawal of consent was the most common reason for discontinuation of treatment.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.1-2"></a>

##### Participant flow by arm with reasons for not completing in the ClinicalTrials.gov results

| Participant flow, overall study | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
| --- | --- | --- | --- | --- | --- | --- |
| Started | “38” | “36” | “36” | “40” | “39” | “39” |
| Completed | “33” | “36” | “30” | “37” | “33” | “35” |
| Not completed | “5” | “0” | “6” | “3” | “6” | “4” |
| Reason: adverse event | “0” | “0” | “2” | “0” | “1” | “1” |
| Reason: discontinued prior to dosing due to the blood sample logistics | “0” | “0” | “0” | “1” | “0” | “0” |
| Reason: lost to follow-up | “0” | “0” | “2” | “1” | “1” | “0” |
| Reason: protocol violation | “0” | “0” | “0” | “0” | “2” | “0” |
| Reason: subject can't continue with week 16 visit | “0” | “0” | “1” | “0” | “0” | “0” |
| Reason: terminated from the study due to sponsor requirements | “0” | “0” | “0” | “1” | “0” | “0” |
| Reason: withdrawal by subject | “5” | “0” | “1” | “0” | “2” | “3” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Demographic and baseline disease characteristics by arm in the intent-to-treat set

| Characteristic | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 40 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 | ESK-001 pooled, N = 190 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Mean age, years (SD) | “49 (11.7)” | “49 (12.7)” | “44 (12.0)” | “48 (12.5)” | “50 (10.4)” | “48 (14.2)” | “48 (12.4)” |
| Male, n (%) | “31 (82)” | “24 (67)” | “24 (67)” | “23 (58)” | “26 (67)” | “26 (67)” | “123 (65)” |
| Female, n (%) | “7 (18)” | “12 (33)” | “12 (33)” | “17 (43)” | “13 (33)” | “13 (33)” | “67 (35)” |
| Race, American Indian or Alaska Native, n (%) | “0 (0)” | “0 (0)” | “1 (3)” | “0 (0)” | “1 (3)” | “0 (0)” | “2 (1)” |
| Race, Asian, n (%) | “4 (11)” | “1 (3)” | “2 (6)” | “2 (5)” | “2 (5)” | “2 (5)” | “9 (5)” |
| Race, Black or African American, n (%) | “3 (8)” | “4 (11)” | “0 (0)” | “1 (3)” | “1 (3)” | “1 (3)” | “7 (4)” |
| Race, Native Hawaiian or Other Pacific Islander, n (%) | “0 (0)” | “1 (3)” | “0 (0)” | “2 (5)” | “0 (0)” | “0 (0)” | “3 (2)” |
| Race, White, n (%) | “27 (71)” | “30 (83)” | “31 (86)” | “34 (85)” | “33 (85)” | “33 (85)” | “161 (85)” |
| Race, other, n (%) | “4 (11)” | “0 (0)” | “2 (6)” | “1 (3)” | “2 (5)” | “1 (3)” | “6 (3)” |
| Race, not reported, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” | “2 (5)” | “2 (1)” |
| Ethnicity, Hispanic or Latino, n (%) | “13 (34)” | “7 (19)” | “14 (39)” | “7 (18)” | “13 (33)” | “11 (28)” | “52 (27)” |
| Ethnicity, not Hispanic or Latino, n (%) | “24 (63)” | “29 (81)” | “21 (58)” | “33 (83)” | “26 (67)” | “28 (72)” | “137 (72)” |
| Ethnicity, not reported, n (%) | “1 (3)” | “0 (0)” | “1 (3)” | “0 (0)” | “0 (0)” | “0 (0)” | “1 (1)” |
| Mean weight, kg (SD) | “94 (21.4)” | “92 (21.3)” | “103 (39.1)” | “95 (24.7)” | “88 (19.1)” | “91 (20.9)” | “94 (26.1)” |
| Mean BMI, kg/m2 (SD) | “32 (6.8)” | “31 (5.9)” | “35 (12.1)” | “32 (7.4)” | “30 (6.4)” | “32 (7.1)” | “32 (8.1)” |
| Mean duration of psoriasis, years (SD) | “20 (11.6)” | “19 (13.4)” | “17 (8.3)” | “22 (12.2)” | “17 (12.4)” | “22 (15.5)” | “19 (12.7)” |
| Prior treatment with biologics or JAK inhibitors, n (%) | “13 (34)” | “13 (36)” | “14 (39)” | “16 (40)” | “13 (33)” | “13 (33)” | “69 (36)” |
| Mean PASI score (SD) | “18 (4.5)” | “17 (3.9)” | “19 (6.6)” | “18 (6.5)” | “17 (6.5)” | “17 (4.9)” | “18 (5.8)” |
| sPGA score 3 (moderate), n (%) | “22 (58)” | “24 (67)” | “17 (47)” | “23 (58)” | “25 (64)” | “23 (59)” | “112 (59)” |
| sPGA score 4 (marked), n (%) | “15 (40)” | “9 (25)” | “17 (47)” | “16 (40)” | “14 (36)” | “16 (41)” | “72 (38)” |
| sPGA score 5 (severe), n (%) | “1 (3)” | “3 (8)” | “2 (6)” | “1 (3)” | “0 (0)” | “0 (0)” | “6 (3)” |
| Mean BSA, % (SD) | “23 (12.1)” | “21 (12.2)” | “20 (12.6)” | “21 (15.0)” | “20 (12.9)” | “22 (15.1)” | “21 (13.5)” |
| Mean DLQI score (SD) | “10 (7.2)” | “10 (5.4)” | “9 (7.6)” | “10 (7.2)” | “10 (6.4)” | “11 (6.8)” | “10 (6.7)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.2-2"></a>

##### Balance across arms and overall prior biologic or JAK inhibitor exposure in the published article

> “Baseline demographics and disease characteristics were generally well-balanced across treatment groups (Table I) and reflected the moderate-to-severe psoriasis population.”
> “Overall, 82 patients (36%) had prior biologics/JAK inhibitor exposure.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.2-3"></a>

##### Age categories by arm in the ClinicalTrials.gov results

| Age category, participants | Placebo, n = 38 | ESK-001 10 mg QD, n = 36 | ESK-001 20 mg QD, n = 36 | ESK-001 20 mg BID, n = 40 | ESK-001 40 mg QD, n = 39 | ESK-001 40 mg BID, n = 39 | Total, n = 228 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 18 years or younger | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| Between 18 and 65 years | “35” | “33” | “33” | “35” | “37” | “33” | “206” |
| 65 years or older | “3” | “3” | “3” | “5” | “2” | “6” | “22” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### PASI 75, PASI 90, PASI 100, sPGA 0/1, sPGA 0, and BSA results at week 12 by dose in the modified intent-to-treat set

| Week 12 end point | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 |
| --- | --- | --- | --- | --- | --- | --- |
| PASI-75, n (%) | “0 (0)” | “7 (19)” | “12 (33)” | “22 (56)” | “22 (56)” | “25 (64)” |
| PASI-75, P value vs placebo | “-” | “0.0025” | “0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
| PASI-75, difference vs placebo, % (95% CI) | “-” | “19 (−3, 41)” | “33 (11, 54)” | “56 (37, 73)” | “56 (37, 73)” | “64 (46, 79)” |
| PASI-90, n (%) | “0 (0)” | “0 (0)” | “4 (11)” | “10 (26)” | “10 (26)” | “15 (39)” |
| PASI-90, P value vs placebo | “-” | “-” | “.0322” | “.0007” | “.0005” | “<.0001” |
| PASI-90, difference vs placebo, % (95% CI) | “-” | “-” | “11 (−12,34)” | “26 (4, 46)” | “26 (4, 46)” | “39 (17, 58)” |
| PASI-100, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “4 (10)” | “3 (8)” | “6 (15)” |
| PASI-100, P value vs placebo | “-” | “-” | “-” | “.0396” | “.0712” | “.0127” |
| PASI-100, difference vs placebo, % (95% CI) | “-” | “-” | “-” | “10 (−12, 32)” | “8 (−15, 30)” | “15 (−7, 37)” |
| sPGA-0/1, n (%) | “3 (8)” | “6 (17)” | “14 (39)” | “19 (49)” | “21 (54)” | “23 (59)” |
| sPGA-0/1, P value vs placebo | “-” | “.1965” | “.0012” | “<.0001” | “<.0001” | “<.0001” |
| sPGA-0/1, difference vs placebo, % (95% CI) | “-” | “9 (−14, 32)” | “31 (8, 51)” | “41 (20, 60)” | “46 (26, 65)” | “51 (31, 69)” |
| sPGA-0, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “4 (10)” | “4 (10)” | “9 (23)” |
| sPGA-0, P value vs placebo | “-” | “-” | “-” | “.0396” | “.0333” | “.0017” |
| sPGA-0, difference vs placebo, % (95% CI) | “-” | “-” | “-” | “10 (−12, 32)” | “10 (−12,32)” | “23 (1, 44)” |
| Mean BSA change from baseline (SD) | “−3 (6.8)” | “−7 (7.8)” | “−7 (8.1)” | “−14 (12.9)” | “−15 (14.2)” | “−14 (12.1)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.3-2"></a>

##### Primary end point, dose-dependent response, and key secondary end points in the published article

> “ESK-001 demonstrated both clinically meaningful and statistically significant dose-dependent improvements in psoriasis skin severity and quality of life”
> “A dose-dependent effect was observed across all end points, with maximal ESK-001 efficacy observed in the highest dose arm (40 mg BID).”
> “More patients achieved PASI-75 in each of the ESK-001 dose arms compared with placebo: 64% in the 40 mg BID dose arm vs 0% in the placebo group (P < .0001) at week 12, meeting the primary end point.”
> “Likewise, all key secondary end points were met in the 20 mg BID, 40 mg QD, and 40 mg BID dose arms.”
> “In patients receiving ESK-001 40 mg BID, 39% (P < .0001) and 15% (P = .0127) achieved PASI-90 and PASI-100, respectively (placebo, 0%).”
> “Furthermore, 59% (P < .0001) and 23% (P = .0017) achieved sPGA-0/1 and sPGA-0, respectively (placebo, 8% and 0%, respectively).”
> “Clinical responses to ESK-001 were robust and increased over time in all ESK-001 dose arms.”
> “In the 3 highest dose groups, clinically meaningful improvements in the primary and all secondary end points were achieved, including PASI, sPGA, DLQI, pruritus, and % body surface area involvement (P < .001).”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.3-3"></a>

##### Maintenance of PASI 75 and PASI 90 responses during the 4 weeks off treatment, and response trajectories at week 12

> “During the 4 weeks off ESK-001 in the safety follow-up period between week 12 and week 16, 83% and 85% of patients in the 40 mg BID dose arm maintained their PASI-75 and PASI-90 responses, respectively.”
> “Clinical responses increased over time, with response trajectories suggesting maximal efficacy not yet achieved at the time of the primary end point (week 12) as noted across other treatments for psoriasis.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.3-4"></a>

##### PASI 75 response rates with 95% confidence intervals in the ClinicalTrials.gov results

| Week 12 outcome | Placebo, n = 38 | ESK-001 10 mg QD, n = 36 | ESK-001 20 mg QD, n = 36 | ESK-001 20 mg BID, n = 39 | ESK-001 40 mg QD, n = 39 | ESK-001 40 mg BID, n = 39 |
| --- | --- | --- | --- | --- | --- | --- |
| PASI-75, percentage (95% CI) | “0 (0.0 to 9.3)” | “19.4 (8.2 to 36.0)” | “33.3 (18.6 to 51.0)” | “56.4 (36.6 to 72.2)” | “56.4 (39.6 to 72.2)” | “64.1 (47.2 to 78.8)” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="topic-3.1.4.8.3-5"></a>

##### Plasma ESK-001 concentrations by dose in the ClinicalTrials.gov results

> “To Characterize the Pharmacokinetics (PK) of ESK-001 Type: Secondary | Time Frame: 14 weeks Description Plasma concentrations and PK parameters of ESK-001.”
> “Mean (Standard Deviation) | Unit of Measure: ng/ml”

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

| Plasma ESK-001 concentration, ng/ml | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
| --- | --- | --- | --- | --- | --- | --- |
| Mean (SD) | “2.9(10.5)” | “11.9(12.4)” | “33.0(49.9)” | “63.9(44.8)” | “50.7(44.8)” | “174.0(125.0)” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="topic-3.1.4.8.3-6"></a>

##### Dose-proportional pharmacokinetics, exposure-response, and trough coverage of the IC90 in the published article

> “PK findings demonstrated dose-dependent linear kinetics.”
> “A positive correlation between ESK-001 exposure and PASI was observed, with patients achieving PASI-90 and PASI-100 having higher mean exposures compared to patients achieving PASI-75”
> “ESK-001 demonstrated a dose-dependent increase in TYK2 inhibition, with the 40 mg BID dose achieving continuous IC90 coverage at trough levels over 24 hours, a key characteristic demonstrating optimized efficacy outcomes.”
> “The observed trough exposure levels (Ctrough = 182 ng/mL) exceeded the in vitro human whole blood IC90 for phosphorylated signal transducer and activator of transcription inhibition (144 ng/mL) throughout the dosing period, indicating sustained and continued TYK2 inhibition over time.”
> “Additionally, the PK findings were consistent with results from studies in healthy volunteers, demonstrating favorable, dose-dependent linear kinetics with minimal variability.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.3-7"></a>

##### Blood SIGLEC1 and lesional skin biomarker results in the published article

> “Transcriptomic analysis confirmed that maximal inhibition of TYK2 occurred with the 40 mg BID dose, as measured by SIGLEC1 via blood RNA-seq, a novel TYK2-sensitive pharmacodynamic biomarker”
> “RNA-seq analyses in skin showed a reduction in key disease biomarkers (including IL-23, IL-17F, and β-defensin in lesional skin following 12 weeks of treatment with ESK-001), with expression levels of IL-17F and IL-23A normalizing to the levels found in nonlesional skin after treatment with 40 mg BID dose”
> “Optional skin punch biopsies were collected from a subset of patients with approximately 5-12 patient samples collected per dose group, consisting of paired lesional and nonlesional samples at baseline, and a lesional sample at week 12.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.3-8"></a>

##### Exploratory exposure-response analysis and selection of the 40 mg twice-daily dose for phase 3

> “Data from 121 healthy subjects and 185 subjects with PsO.”
> “Cavg of ESK-001 was categorized into four exposure groups or bins (Bin 1 = placebo, Bin 2-4 = tertiles of exposure from low to high; number of subjects is about equal for each bin).”
> “STRIDE Week 12 Cavg probability distribution by exposure bins showed that 40 mg BID had substantially higher exposures overall and thus, would be expected to have the strongest efficacy.”
> “The exploratory E-R analyses demonstrated an exposure-dependent increase in key efficacy endpoints PASI-75, sPGA 0/1, and %BSA change responses.”
> “Maximal therapeutic response was achieved at 40 mg BID dose, which maintained a safety profile comparable to lower tested doses. Hence, 40 mg BID dose was selected for the upcoming Phase III studies in subjects with moderate-to-severe plaque PsO.”

Source: [Ucpinar et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv2024_pstr_poppk-er_final.pdf)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

##### DLQI 0/1, DLQI 4-point decrease, and pruritus NRS results at week 12 by dose in the modified intent-to-treat set

| Week 12 patient-reported outcome | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 |
| --- | --- | --- | --- | --- | --- | --- |
| DLQI-0/1, n (%) | “7 (18)” | “10 (28)” | “12 (33)” | “20 (51)” | “19 (48)” | “25 (64)” |
| DLQI-0/1, P value vs placebo | “-” | “.2807” | “.1159” | “.0016” | “.0045” | “<.0001” |
| DLQI-0/1, difference vs placebo, % (95% CI) | “-” | “9 (−10, 29)” | “15 (−5, 35)” | “33 (13, 53)” | “30 (10, 50)” | “46 (26, 65)” |
| DLQI 4-point decrease, n (%) | “7 (19)” | “18 (51)” | “18 (51)” | “25 (64)” | “26 (70)” | “24 (65)” |
| DLQI 4-point decrease, P value vs placebo | “-” | “.0032” | “.0032” | “.0001” | “<.0001” | “<.0001” |
| DLQI 4-point decrease, difference vs placebo, % (95% CI) | “-” | “33 (12, 53)” | “33 (12, 53)” | “45 (26, 65)” | “51 (32, 71)” | “46 (26, 66)” |
| Mean change from baseline in average pruritus NRS (SD) | “−1 (3)” | “−2 (3)” | “−3 (3)” | “−4 (3)” | “−4 (3)” | “−5 (3)” |
| Mean change from baseline in worst pruritus NRS (SD) | “−1 (3)” | “−3 (3)” | “−3 (4)” | “−4 (3)” | “−5 (3)” | “−5 (3)” |
| Average pruritus NRS score <4, n (%) | “11 (29)” | “17 (47)” | “21 (58)” | “27 (69)” | “27 (69)” | “28 (72)” |
| Worst pruritus NRS score <4, n (%) | “10 (26)” | “17 (47)” | “18 (50)” | “26 (67)” | “27 (69)” | “29 (74)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.4-2"></a>

##### DLQI 0/1 and average pruritus NRS improvement with 40 mg twice daily in the published article

> “Improvements in skin severity end points were accompanied by dose-dependent improvements in patient-reported outcomes, as demonstrated by changes in DLQI and pruritus, with 64% of patients who received ESK-001 40 mg BID achieving a DLQI of 0/1 versus 18% with placebo (P < .0001).”
> “Additionally, the average pruritus numerical rating scale score improved by 5 points with ESK-001 40 mg BID versus 1 point with placebo at week 12 (P < .0001) (Table II).”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.4-3"></a>

##### Median change in average and worst pruritus NRS at week 12 by dose in the congress poster

| Week 12 pruritus NRS change from baseline, median (IQR) | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 |
| --- | --- | --- | --- | --- | --- | --- |
| Average pruritus NRS | “0.0 (-3.0, 1.0)” | “-2.0 (-3.0, 0.0)” | “-2.5 (-6.0, 0.0)” | “-3.0 (-5.0, -2.0)” | “-5.0 (-6.0, -3.0)” | “-4.0 (-8.0, -3.0)” |
| Worst pruritus NRS | “-0.5 (-2.0, 1.0)” | “-2.0 (-4.0, -1.0)” | “-2.5 (-5.0, 1.0)” | “-4.0 (-6.0, -1.0)” | “-5.0 (-7.0, -3.0)” | “-5.0 (-7.0, -3.0)” |

Source: [Blauvelt et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/eadv_2024_pstr-pro_ole.pdf)

<a id="topic-3.1.4.8.4-4"></a>

##### DLQI reductions of at least 4, 5, and 6 points with 40 mg twice daily and pruritus NRS of 3 or less in the congress poster

> “Largest clinically meaningful reductions in DLQI at highest ESK-001 dose (40 mg BID) in STRIDE study.”
> “62% had ≥4 point reduction, 54% had ≥5 point reduction, 51% had ≥6 point reduction.”
> “Significantly more patients achieved pruritus NRS ≤3 when treated with three highest ESK-001 doses compared to placebo (p<0.001 vs placebo).”

Source: [Blauvelt et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/eadv_2024_pstr-pro_ole.pdf)

<a id="topic-3.1.4.8.4-5"></a>

##### EQ-5D results

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Treatment-emergent adverse events by dose in the safety analysis set

| Outcome, n (%) | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 | ESK-001 pooled, N = 189 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| TEAEs | “15 (39.5)” | “19 (52.8)” | “14 (38.9)” | “18 (46.2)” | “19 (48.7)” | “25 (64.1)” | “95 (50.3)” |
| TEAEs leading to treatment discontinuation | “0 (0.0)” | “0 (0.0)” | “2 (5.6)” | “0 (0.0)” | “2 (5.1)” | “1 (2.6)” | “5 (2.6)” |
| TEAEs grade 3 or higher | “0 (0.0)” | “3 (8.3)” | “1 (2.8)” | “3 (7.7)” | “3 (7.7)” | “0 (0.0)” | “10 (5.3)” |
| TEAEs related to study drug | “5 (13.2)” | “3 (8.3)” | “3 (8.3)” | “5 (12.8)” | “7 (17.9)” | “9 (23.1)” | “27 (14.3)” |
| Headache | “2 (5.3)” | “0 (0.0)” | “2 (5.6)” | “3 (7.7)” | “4 (10.3)” | “3 (7.7)” | “12 (6.3)” |
| Upper respiratory tract infection | “0 (0.0)” | “2 (5.6)” | “2 (5.6)” | “1 (2.6)” | “2 (5.1)” | “3 (7.7)” | “10 (5.3)” |
| Nasopharyngitis | “3 (7.9)” | “2 (5.6)” | “0 (0.0)” | “1 (2.6)” | “1 (2.6)” | “3 (7.7)” | “7 (3.7)” |
| SAEs | “0 (0.0)” | “1 (2.8)” | “0 (0.0)” | “3 (7.7)” | “1 (2.6)” | “0 (0.0)” | “5 (2.6)” |
| Deaths | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

> “TEAEs leading to treatment discontinuation in 5 patients included eczema (20 mg QD), arthralgia (20 mg QD), blood triglyceride increased (40 mg QD), dermatitis contact (40 mg QD), and urticaria (40 mg BID).”
> “TEAEs reported by 3 or more patients in any treatment group.”
> “All events of headache were grade 1 (mild) or grade 2 (moderate) in severity and most were resolved by the end of the study.”
> “All events of upper respiratory tract infection and nasopharyngitis were grade 1 (mild) or grade 2 (moderate) in severity and all were resolved by the end of the study.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.5-2"></a>

##### Overall tolerability, common adverse events, and absence of tuberculosis, herpes zoster, opportunistic infections, and oral ulcers in the published article

> “ESK-001 was generally safe and well-tolerated in adult patients with moderate-to-severe psoriasis following 12 weeks of treatment and 4 weeks off treatment, with no dose-limiting safety findings and a study drug discontinuation rate of 2.6% due to AEs”
> “There were no deaths in this study.”
> “Overall, the most common AEs (occurring in >5% of patients in any treatment group) were headache (6.3%), upper respiratory tract infections (5.3%), and nasopharyngitis (3.7%).”
> “Rates of acne and folliculitis were 2.1% and 1.6%, respectively, with no dose dependency (data on file).”
> “AEs were reported in 40% and in 39% to 64% of the patients in the placebo group and active-drug groups, respectively, with the highest percentage in the 40 mg BID dose group.”
> “TEAEs related to study drug occurred in 23% of subjects receiving 40 mg BID dose, 14.3% of subjects in pooled ESK-001 groups, and 13.2% of placebo subjects.”
> “Across all groups, the majority of TEAEs were mild or moderate and resolved.”
> “There were no cases of tuberculosis, herpes zoster, opportunistic infections, or oral ulcers.”
> “In addition, laboratory and electrocardiogram findings showed no meaningful changes during 12 weeks of ESK-001 treatment”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.5-3"></a>

##### Serious adverse events by arm, with the gastrointestinal event in the 20 mg twice-daily arm reported as enterocolitis, enteritis, or colitis and enteritis

> “SAEs: lower limb fracture (10 mg QD), tibia fracture (20 mg BID), coronary artery occlusion (20 mg BID), enterocolitis (20 mg BID), dermatitis contact (40 mg QD); all assessed by investigators as unrelated to a study drug.”
> “Five serious adverse events were reported and none were considered by the investigator to be related to study drug: 2 cases of limb fracture from trauma, contact dermatitis following exposure to a known allergen, an incidental asymptomatic computed tomography scan finding of coronary artery occlusion successfully treated with cardiac catheterization, and enteritis (etiology unknown) which resolved with no study drug discontinuation.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

| Serious adverse event, affected / at risk (%) | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
| --- | --- | --- | --- | --- | --- | --- |
| Total | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “3/39 (7.69%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |
| Coronary artery occlusion | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Colitis | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Enteritis | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Lower limb fracture | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Tibia fracture | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Dermatitis contact | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

> “SAEs (all unrelated): Lower limb fracture (10mg QD), tibia fracture (20mg BID), coronary artery occlusion (20mg BID), colitis and enteritis in one subject (20mg BID), dermatitis contact (40mg QD).”

Source: [Papp et al. (2024)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_2_for_website_aad_pres_vf.pdf)

<a id="topic-3.1.4.8.5-4"></a>

##### Other adverse events reported in at least 5% of participants in any arm in the ClinicalTrials.gov results

> “Adverse Event data was collected from Screening through end of study (Week 16).”
> “5% Frequency Threshold for Reporting Other Adverse Events”

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

| Other (not serious) adverse event, affected / at risk (%) | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
| --- | --- | --- | --- | --- | --- | --- |
| Total | “9/38 (23.68%)” | “8/36 (22.22%)” | “4/36 (11.11%)” | “18/39 (46.15%)” | “11/39 (28.21%)” | “18/39 (46.15%)” |
| Diarrhea | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “2/39 (5.13%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |
| Dyspepsia | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “2/39 (5.13%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Nausea | “1/38 (2.63%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “2/39 (5.13%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Pyrexia | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “2/39 (5.13%)” |
| Upper respiratory tract infection | “0/38 (0.00%)” | “2/36 (5.56%)” | “2/36 (5.56%)” | “1/39 (2.56%)” | “2/39 (5.13%)” | “3/39 (7.69%)” |
| Nasopharyngitis | “3/38 (7.89%)” | “2/36 (5.56%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “1/39 (2.56%)” | “3/39 (7.69%)” |
| COVID-19 | “3/38 (7.89%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “1/39 (2.56%)” |
| Diabetes mellitus | “0/38 (0.00%)” | “2/36 (5.56%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Headache | “2/38 (5.26%)” | “0/36 (0.00%)” | “2/36 (5.56%)” | “3/39 (7.69%)” | “4/39 (10.26%)” | “3/39 (7.69%)” |
| Dizziness | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “2/39 (5.13%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |
| Cough | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “2/39 (5.13%)” | “0/39 (0.00%)” | “2/39 (5.13%)” |
| Acne | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “2/39 (5.13%)” | “2/39 (5.13%)” |
| Dermatitis acneiform | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “0/39 (0.00%)” | “2/39 (5.13%)” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="topic-3.1.4.8.5-5"></a>

##### Absence of dose-dependent safety signals and of JAK inhibitor-associated adverse events in the discussion of the published article

> “No dose-dependent safety signals were identified, and the overall safety profile of ESK-001 was consistent with long-term safety analyses up to 4 years reported for deucravacitinib, another TYK2 inhibitor, with no new safety findings.”
> “Of note, the safety profile of ESK-001 did not demonstrate any AEs associated with JAK inhibitor safety findings, such as serious infections, increased mortality, malignancy, major adverse cardiovascular events, and thrombosis.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.5-6"></a>

##### Absence of MACE, serious infections, treatment-related thromboses, and laboratory or ECG trends in the congress presentation

> “Note: no MACE, serious infections, treatment related thromboses or concerning lab/ECG trends were observed.”

Source: [Papp et al. (2024)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_2_for_website_aad_pres_vf.pdf)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

- The authors cite the small sample size per treatment group and the 16-week study duration, and the exclusion of participants who were previously nonresponders to IL-17, IL-12, or IL-23 targeted therapies. The protocol also excluded participants with lack of response to 2 or more biologic therapies.
- The primary endpoint was assessed at week 12, when, according to the authors, response trajectories suggested maximal efficacy had not yet been achieved.
- The statistical analysis plan states that no adjustments for multiplicity were performed.
- The analysis population for efficacy differs by source: the protocol planned intent-to-treat analyses, the article used the modified intent-to-treat population, and the ClinicalTrials.gov results describe the PASI 75 population as all randomized and treated participants. The 20 mg BID arm has 40 participants in the intent-to-treat set and 39 in the modified intent-to-treat and safety sets.
- The number of sites is 30 in the article, 53 in the ClinicalTrials.gov record, and approximately 65 planned in the protocol.
- The serious gastrointestinal event in the 20 mg BID arm is reported as enterocolitis (article table footnote), enteritis of unknown etiology (article text), colitis and enteritis as separate terms (ClinicalTrials.gov results), and colitis and enteritis in one subject (congress presentation).
- The article reports 5 participants (2.6%) discontinuing envudeucitinib due to an AE; the ClinicalTrials.gov participant flow lists an adverse event as the reason for not completing the study for 2 (20 mg QD), 1 (40 mg QD), and 1 (40 mg BID) participants.
- The DLQI decrease of at least 4 points with 40 mg BID is 65% in the article and 62% in the patient-reported outcomes poster.
- Acne and folliculitis rates are cited as data on file, skin biopsies were optional and collected from approximately 5 to 12 participants per dose group, and the report holds no EQ-5D results.

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext); [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036); [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results); [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf); [Alumis STRIDE statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/SAP_001.pdf); [Blauvelt et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/eadv_2024_pstr-pro_ole.pdf); [Papp et al. (2024)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_2_for_website_aad_pres_vf.pdf)

<a id="topic-3.1.4.9-2"></a>

#### Limitations stated by the authors: sample size, duration, and exclusion of prior nonresponders to IL-17, IL-12, or IL-23 therapies

> “Limitations of this phase 2 study include small sample size per treatment group and 16-week study duration.”
> “Considering the pathway modulated by TYK2 inhibition, patients who were previously nonresponders to IL-17/IL-12/IL-23 targeted therapies were excluded in this phase 2 study.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
